Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,981.00    -2.00 (-0.10%)
Bid:
1,981.00
Ask:
1,981.50
Spread: 0.50 (0.025%)
Market Cap: £79.37b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

13 Nov 2023 15:30

RNS Number : 2738T
GSK PLC
13 November 2023

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2325

9 (partnership shares)

£14.2325

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.2325

e)

Date of the transaction

2023-11-09

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2325

9 (partnership shares)

£14.2325

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.2325

e)

Date of the transaction

2023-11-09

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2325

9 (partnership shares)

£14.2325

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.2325

e)

Date of the transaction

2023-11-09

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2325

9 (partnership shares)

£14.2325

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.2325

e)

Date of the transaction

2023-11-09

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2325

9 (partnership shares)

£14.2325

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.2325

e)

Date of the transaction

2023-11-09

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2325

8 (partnership shares)

£14.2325

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£14.2325

e)

Date of the transaction

2023-11-09

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Phil Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2325

9 (partnership shares)

£14.2325

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.2325

e)

Date of the transaction

2023-11-09

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2325

8 (partnership shares)

£14.2325

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£14.2325

e)

Date of the transaction

2023-11-09

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.2325

9 (partnership shares)

£14.2325

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.2325

e)

Date of the transaction

2023-11-09

f)

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFFIFDDEDSELF
Date   Source Headline
25th Mar 20257:00 amRNSTransaction in Own Shares
24th Mar 20254:10 pmRNSNotice of AGM
24th Mar 20257:05 amRNSEMA Filing acceptance for Nucala COPD
24th Mar 20257:00 amRNSTransaction in Own Shares
21st Mar 20253:30 pmRNSDirector/PDMR Shareholding
21st Mar 20257:00 amRNSTransaction in Own Shares
20th Mar 20257:00 amRNSTransaction in Own Shares
19th Mar 20257:00 amRNSTransaction in Own Shares
18th Mar 20257:00 amRNSTransaction in Own Shares
17th Mar 20257:00 amRNSTransaction in Own Shares
14th Mar 20253:30 pmRNSDirector/PDMR Shareholding
14th Mar 20257:00 amRNSTransaction in Own Shares
13th Mar 20257:00 amRNSTransaction in Own Shares
12th Mar 20257:00 amRNSTransaction in Own Shares
11th Mar 20257:00 amRNSTransaction in Own Shares
10th Mar 20257:00 amRNSTransaction in Own Shares
7th Mar 20257:00 amRNSTransaction in Own Shares
6th Mar 20257:00 amRNSTransaction in Own Shares
5th Mar 20257:00 amRNSTransaction in Own Shares
4th Mar 20257:00 amRNSTransaction in Own Shares
3rd Mar 20255:15 pmRNSGSK plc 2024 Annual Report on Form 20-F
3rd Mar 20253:00 pmRNSTotal Voting Rights
3rd Mar 20257:05 amRNSUS FDA accept 2 depemokimab indication submissions
3rd Mar 20257:00 amRNSANCHOR results presented at 2025 AAAAI
3rd Mar 20257:00 amRNSTransaction in Own Shares
28th Feb 20257:00 amRNSTransaction in Own Shares
27th Feb 202510:00 amRNSGSK publishes Annual Report 2024
27th Feb 20257:00 amRNSTransaction in Own Shares
26th Feb 20254:00 pmRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSTransaction in Own Shares
25th Feb 20257:00 amRNSTransaction in Own Shares
24th Feb 20257:05 amRNSGSK completes acquisition of IDRx, Inc.
24th Feb 20257:00 amRNSGSK plc commences share buyback programme
21st Feb 20257:00 amRNSDirectorate Change
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
20th Feb 20257:00 amRNSNucala COPD submission accepted in China
17th Feb 20257:00 amRNSGSK 5-in-1 meningitis vaccine approved by US FDA
13th Feb 20253:30 pmRNSDirector/PDMR Shareholding
11th Feb 20253:30 pmRNSDirector/PDMR Shareholding
5th Feb 20257:00 amRNSFinal Results
3rd Feb 20254:48 pmRNSTotal Voting Rights
28th Jan 20257:05 amRNSDepemokimab dual filing in China and Japan
28th Jan 20257:00 amRNSEMA accepts two submissions for depemokimab
27th Jan 20257:05 amRNSEMA accept review Shingrix syringe presentation
20th Jan 20257:00 amRNSJemperli expanded approval in the EU

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.